Scarica l'app Stockscreener
9.66
0.21%
-0.02
Dopo l'orario di chiusura:
9.66
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FOLD Giù?
Forum
Previsione
Precedente Chiudi:
$9.68
Aprire:
$9.93
Volume 24 ore:
2.22M
Relative Volume:
0.94
Capitalizzazione di mercato:
$2.89B
Reddito:
$455.66M
Utile/perdita netta:
$-119.54M
Rapporto P/E:
-15.09
EPS:
-0.64
Flusso di cassa netto:
$-48.10M
1 W Prestazione:
-9.64%
1M Prestazione:
-18.82%
6M Prestazione:
+0.94%
1 anno Prestazione:
-10.39%
Intervallo 1D:
$9.60
$10.04
Intervallo di 1 settimana:
$9.60
$10.83
Portata 52W:
$9.02
$14.57
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Nome
Amicus Therapeutics Inc
Settore
Industria
Telefono
(609) 662-2000
Indirizzo
47 HULFISH STREET, PRINCETON, NJ
Confronta FOLD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
| FOLD | 9.66 | 2.89B | 455.66M | -119.54M | -48.10M | -0.64 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-06 | Iniziato | Jefferies | Buy |
| 2024-05-30 | Iniziato | Wells Fargo | Overweight |
| 2024-05-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-04-13 | Ripresa | Goldman | Neutral |
| 2022-01-14 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | Aggiornamento | Stifel | Hold → Buy |
| 2021-09-30 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-07-19 | Ripresa | BTIG Research | Buy |
| 2021-05-27 | Iniziato | Needham | Hold |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-14 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | Iniziato | Stifel | Hold |
| 2021-02-12 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-12-28 | Ripresa | Cantor Fitzgerald | Overweight |
| 2020-12-10 | Downgrade | Citigroup | Buy → Neutral |
| 2020-11-11 | Iniziato | Berenberg | Hold |
| 2020-06-17 | Iniziato | BTIG Research | Buy |
| 2020-02-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2019-11-12 | Reiterato | H.C. Wainwright | Buy |
| 2019-06-17 | Iniziato | H.C. Wainwright | Buy |
| 2019-06-05 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-05 | Iniziato | Janney | Buy |
| 2019-01-30 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-10-29 | Iniziato | Citigroup | Neutral |
| 2018-08-17 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | Ripresa | Goldman | Neutral |
| 2017-09-13 | Reiterato | Chardan Capital Markets | Buy |
| 2017-08-10 | Reiterato | Chardan Capital Markets | Buy |
| 2017-01-24 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | Iniziato | BofA/Merrill | Buy |
| 2016-04-14 | Iniziato | Robert W. Baird | Neutral |
| 2016-04-12 | Reiterato | Chardan Capital Markets | Buy |
| 2015-09-16 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | Reiterato | Chardan Capital Markets | Buy |
Mostra tutto
Amicus Therapeutics Inc Borsa (FOLD) Ultime notizie
Amicus Therapeutics (NASDAQ:FOLD) Rating Increased to Buy at StockNews.com - MarketBeat
Redmile Group, LLC Increases Stake in Amicus Therapeutics Inc - GuruFocus.com
Protein Therapeutics Market Size to be Worth USD 549.4 billion by 2031, at a CAGR of 6.3% | Transparency Market Research, Inc. - GlobeNewswire Inc.
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC Acquires Shares in Amic - GuruFocus.com
Amicus' Q3 Earnings & Revenues Beat Estimates, '24 View Updated - MSN
Avoro Capital Advisors LLC Adjusts Stake in Amicus Therapeutics Inc - GuruFocus.com
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Purchased by GSA Capital Partners LLP - MarketBeat
A Closer Look at 8 Analyst Recommendations For Amicus Therapeutics - Benzinga
The Analyst Verdict: Amicus Therapeutics In The Eyes Of 8 Experts - Benzinga
Amicus Therapeutics Stock: A Deep Dive Into Analyst Perspectives (8 Ratings) - Benzinga
Amicus Therapeutics (NASDAQ:FOLD) Price Target Raised to $17.00 - MarketBeat
FOLDAmicus Therapeutics, Inc Latest Stock News & Market Updates - StockTitan
Here's Why Amicus Therapeutics (NASDAQ:FOLD) Has A Meaningful Debt Burden - Simply Wall St
Fiera Capital Corp Reduces Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Wellington Management Group LLP's Strategic Acquisition in Amicu - GuruFocus.com
Amicus Therapeutics CEO Campbell sells $98,800 in stock - Investing.com India
Amicus Therapeutics CEO Campbell sells $98,800 in stock By Investing.com - Investing.com Australia
Amicus Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Amicus Therapeutics (NASDAQ:FOLD) Downgraded by StockNews.com to Hold - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Given New $15.00 Price Target at Guggenheim - MarketBeat
Teva’s Galafold generic for Fabry disease may be available in US - Fabry Disease News
Here's Why Amicus Therapeutics (FOLD) is a Strong Momentum Stock - Yahoo Finance
Needham & Company LLC Reiterates Hold Rating for Amicus Therapeutics (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q3 2024 Earnings Call Transcript - Insider Monkey
Peeling Back The Layers: Exploring Amicus Therapeutics Through Analyst Insights - Benzinga
Here's What Key Metrics Tell Us About Amicus Therapeutics (FOLD) Q3 Earnings - Yahoo Finance
Earnings call: Amicus Therapeutics reports robust Q3 growth, raises guidance - Investing.com India
Earnings call: Amicus Therapeutics reports robust Q3 growth, raises guidance By Investing.com - Investing.com Canada
Amicus Therapeutics Q3 2024 Earnings Preview - MSN
Old West Investment Management LLC Grows Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics (FOLD) Q3 Earnings and Revenues Beat Estimates - Yahoo Finance
Amicus Therapeutics Inc (FOLD) Q3 2024 Earnings: Revenue Surges - GuruFocus.com
Amicus Therapeutics: Q3 Earnings Snapshot - San Antonio Express-News
Amicus Therapeutics Announces Third Quarter 2024 Financial Results and Corporate Updates - The Manila Times
Creative Planning Increases Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Bradley L. Campbell Sells 7,500 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) Stock - MarketBeat
Amicus Therapeutics CEO Bradley Campbell sells $85,959 in stock By Investing.com - Investing.com Canada
Wall Street Analysts Predict a 51.09% Upside in Amicus Therapeutics (FOLD): Here's What You Should Know - MSN
Allspring Global Investments Holdings LLC Has $172,000 Stock Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Brokerages Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) PT at $17.13 - Defense World
Blue Trust Inc. Boosts Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2024 - GlobeNewswire
Analysts Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) PT at $17.13 - MarketBeat
abrdn plc Boosts Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Stock Rating Lowered by StockNews.com - Defense World
Amicus Therapeutics (FOLD) Reports Next Week: Wall Street Expects Earnings Growth - Yahoo Finance
Amicus Therapeutics (FOLD) Scheduled to Post Quarterly Earnings on Wednesday - MarketBeat
Semanteon Capital Management LP Invests $1.13 Million in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics to Announce Third Quarter 2024 Financial Results on November 6, 2024 - GlobeNewswire
Amicus Therapeutics Inc Azioni (FOLD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.66%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):